48.13
price down icon0.50%   -0.24
pre-market  プレマーケット:  48.49   0.36   +0.75%
loading

Sanofi Adr (SNY) 最新ニュース

pulisher
Jan 07, 2026

Regeneron Just Moved From Underperform To Buy - Benzinga

Jan 07, 2026
pulisher
Jan 06, 2026

FDA Flags Liver Injury Risk In Sanofi's Rejected Multiple Sclerosis Drug - Benzinga

Jan 06, 2026
pulisher
Jan 05, 2026

KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz

Jan 05, 2026
pulisher
Jan 05, 2026

FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Finviz

Jan 05, 2026
pulisher
Jan 02, 2026

REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz

Jan 02, 2026
pulisher
Dec 31, 2025

Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm

Dec 31, 2025
pulisher
Dec 30, 2025

Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz

Dec 30, 2025
pulisher
Dec 30, 2025

Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies CorporationDVAX - Sahm

Dec 30, 2025
pulisher
Dec 30, 2025

Where is Sanofi (SNY) Headed According to Wall Street? - Finviz

Dec 30, 2025
pulisher
Dec 29, 2025

Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz

Dec 29, 2025
pulisher
Dec 28, 2025

Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz

Dec 28, 2025
pulisher
Dec 25, 2025

Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets

Dec 25, 2025
pulisher
Dec 24, 2025

Why Dynavax Stock Soared Today - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz

Dec 24, 2025
pulisher
Dec 24, 2025

Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm

Dec 24, 2025
pulisher
Dec 24, 2025

Our Environmental Impact - Sanofi

Dec 24, 2025
pulisher
Dec 21, 2025

Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends

Dec 21, 2025
pulisher
Dec 17, 2025

Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz

Dec 17, 2025
pulisher
Dec 16, 2025

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 16, 2025
pulisher
Dec 15, 2025

Sanofi (SNY) sees slight pessimism from analysts - MSN

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi: Today's Tolebrutinib Setback Shouldn't Worry ShareholdersThis Is Why (SNY) - Seeking Alpha

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration - Sahm

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks - Sahm

Dec 15, 2025
pulisher
Dec 15, 2025

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025) - ts2.tech

Dec 15, 2025
pulisher
Dec 14, 2025

SNY Stock Price and Chart — NASDAQ:SNY - TradingView — Track All Markets

Dec 14, 2025
pulisher
Dec 12, 2025

Sanofi (SNY) Sees Slight Pessimism From Analysts - Finviz

Dec 12, 2025
pulisher
Dec 10, 2025

JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105 - Finviz

Dec 10, 2025
pulisher
Dec 10, 2025

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz

Dec 10, 2025
pulisher
Dec 10, 2025

Why Wall Street Analysts Are Closely Watching Sanofi (SNY) - Finviz

Dec 10, 2025
pulisher
Dec 09, 2025

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz

Dec 09, 2025
pulisher
Dec 09, 2025

KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz

Dec 09, 2025
pulisher
Dec 09, 2025

Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Sahm

Dec 09, 2025
pulisher
Dec 01, 2025

REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 01, 2025
pulisher
Nov 28, 2025

Deutsche Bank Maintains a Buy Rating on Sanofi (SNY) - Finviz

Nov 28, 2025
pulisher
Nov 26, 2025

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Nov 26, 2025
drug_manufacturers_general PFE
$25.29
price up icon 0.04%
$120.67
price down icon 2.96%
$330.11
price down icon 3.37%
drug_manufacturers_general NVO
$57.34
price up icon 1.36%
drug_manufacturers_general NVS
$141.46
price down icon 0.37%
大文字化:     |  ボリューム (24 時間):